Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Investor Presentation (July 2020)
12 slides from Atomo Diagnostics's investor presentation, Jul 29, 2020
Slide 1: Atomo Diagnostics Investor Update
For personal use only Atomo Diagnostics Limited (ASX: AT1) Investor Update 29 July 2020 This announcement was authorised by John Kelly, Managing Director Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”), person, accepts any responsibility or liability for the content of this presentation This presentation may contains certain forward looking statements that are based based on information avai
Slide 3: Introduction
Introduction Atomo Diagnostics Limited (“Atomo”) (ASX: AT1) is a medical device For personal use only company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market • Headquartered in Australia with staff in Europe and Africa, Atomo develops and manufactures
Slide 4: Current Business Focus
Current Business Focus HIV Self-Test For personal use only • Atomo’s HIV self-test has secured regulatory approval in Australia (TGA) and Europe (CE Mark) and is prequalified by the World Health Organisation (WHO) • Mylan and Owen Mumford - rolling out globally COVID-19 • Atomo devices in high deman
Slide 5: Corporate
Corporate Key financial details Share price performance For personal use only ASX code $AT1 $ Share price (28/07/20) $0.40 Shares on issue 561.1m Options on issue 31.7m IPO @ 20c Market cap* $225m Current cash (30/6/20) $27.1m *Undiluted Major Shareholders % (undiluted) Board and Management Dalraida
Slide 6: Investment Highlights
Investment Highlights For personal use only Proven technology - the world’s first fully integrated, blood-based rapid lateral flow tests Large global market - US$4.57 billion1 lateral flow test revenues recorded globally in 2019 Multiple revenue streams secured from multiple diagnostic applications
Slide 7: Patented Protected Solutions
Patented Protected Solutions • Atomo has developed a range of unique, integrated devices for blood-based rapid diagnostic testing For personal use only • The test process can be completed in just three simple user steps, with the result provided after 15 minutes * The Atomo Elion device shown above
Slide 8: Progress since IPO
Progress since IPO For personal use only Atomo secures supply Atomo and NG Biotech Atomo Quarterly Additional deal with NG Biotech for expand COVID-19 FY20 Revenue* manufacturing COVID-19 antibody rapid partnership to include exceeds $5m. capacity anticipated – testing (RDT) in France & ANZ and SE A
Slide 9: COVID-19 Contracts
COVID-19 Contracts Customers Key terms Update and opportunity NG Biotech SAS • 2.46m devices to be ordered in CY20 • 1.75m units ordered to date for France For personal use only • Existing Atomo partner – • CE Marked COVID-19 test on Atomo • Sales to French Ministry of Defense and Public Health preg
Slide 10: Q4 FY20 – Quarterly Update
Q4 FY20 – Quarterly Update • Cash receipts for Q4 FY20 of $1.84m more than double Q1-Q3 FY20 combined For personal use only • Revenues for FY20 (unaudited) in excess of $5 million: approximately 10 x FY19 revenue • $30m of cash into the company via IPO deployed as per Use of Funds from the Prospectu
Slide 11: Outlook
Outlook • Support and grow a global COVID-19 business through partnerships with For personal use only NG Biotech and Access Bio contract • Continue to deliver manufacturing scale up for Galileo and Pascal • Ongoing roll-out of our HIV Self-Test business • Expansion of sales of OEM products to existi
Slide 12: John Kelly, Managing Director
For personal use only John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com
Atomo Diagnostics — Investor Presentation (July 2020) on 6ix